AROA BIOSURGERY LIMITED (ARX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ARX

ARX - AROA BIOSURGERY LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 6.8
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.63

14 Aug
2025

-0.010

OPEN

$0.63

-1.56%

HIGH

$0.64

82,851

LOW

$0.63

TARGET
$0.81 28.6% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
ARX: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 1.0 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 62.7 xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-1.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx77.1 M
Book Value Per Share xxxxxxxxxxxxxxx24.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-2.3 M
Net Profit Margin xxxxxxxxxxxxxxx-4.50 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-4.04 %
Return on Invested Capital xxxxxxxxxxxxxxx-3.81 %
Return on Assets xxxxxxxxxxxxxxx-3.46 %
Return on Equity xxxxxxxxxxxxxxx-4.04 %
Return on Total Capital xxxxxxxxxxxxxxx-3.96 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-4.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx5 M
Total Debt xxxxxxxxxxxxxxx6 M
Goodwill - Gross xxxxxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx20 M
Price To Book Value xxxxxxxxxxxxxxx1.73

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx3.4 M
Capex % of Sales xxxxxxxxxxxxxxx4.37 %
Cost of Goods Sold xxxxxxxxxxxxxxx11 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx70 M
Research & Development xxxxxxxxxxxxxxx9 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

30/05/2025

1

Buy

$0.85

34.92%

Aroa Biosurgery's FY25 revenue slightly beat the company's own guidance, with currency tailwind as one of the factors, though 2H revenues also jumped materially vs 1H.

Bell Potter notes costs are well-controlled and in line with revenue growth. The company expects FY26 revenue of NZ$92-100m, which the broker believes is conservative, but still lowered its forecast to NZ$103m from NZ$109m.

The analyst also expects FY26 EBITDA to be above the company's guidance. Buy. Target unchanged at 85c.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.91 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.65 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

14/08/2025

1

Buy

$0.90

42.86%

Canaccord Genuity highlights 2Q results of Aroa Biosurgery's distribution partner TELA Bio and guidance has positive implications for the company.

TELA's 2Q revenue grew 9% q/q on strong PRS growth and continued OviTex unit demand. Moreover, the company maintained FY25 guidance which bodes well for Aroa's outlook, given its conservative modelling for FY26 TELA's contribution.

Note: TELA's financial year ends December, while Aroa's ends March.

Buy. Target unchanged at 90c.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.92 cents.
Access Extra Coverage Research History >

ARX STOCK CHART

FNArena News on ARX

1
Australian Broker Call *Extra* Edition – Aug 14, 2025

Aug 14 2025 - Daily Market Reports
2
In Case You Missed It – BC Extra Upgrades & Downgrades – 06-06-25

Jun 06 2025 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Jun 04, 2025

Jun 04 2025 - Daily Market Reports
4
FNArena Corporate Results Monitor – 30-05-2025

May 30 2025 - Australia
5
Weekly Ratings, Targets, Forecast Changes – 09-05-25

May 12 2025 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
2
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
3
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
4
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
5
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
6
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
7
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
8
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
9
CSL Shares Breaking Free

Jul 23 2024 - Technicals
10
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps